Table of Contents

Last Updated: July 8, 2021

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

The COVID-19 Treatment Guidelines Panel’s Statement on the Updated Emergency Use Authorization of the Anti-SARS-CoV-2 Monoclonal Antibody Combination Casirivimab Plus Imdevimab for the Treatment of COVID-19

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorizations of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19

Introduction

Overview

• Overview of COVID-19
• Testing for SARS-CoV-2 Infection
• Prevention and Prophylaxis of SARS-CoV-2 Infection
• Clinical Spectrum of SARS-CoV-2 Infection

Clinical Management

• Clinical Management Summary
• General Management of Nonhospitalized Patients With COVID-19
• Therapeutic Management of Nonhospitalized Adults With COVID-19
• Therapeutic Management of Hospitalized Adults With COVID-19

Critical Care

• Care of Critically Ill Adult Patients With COVID-19 (Summary Recommendations)
• General Considerations
• Infection Control
• Hemodynamics
• Oxygenation and Ventilation
• Acute Kidney Injury and Renal Replacement Therapy
• Pharmacologic Interventions
• Extracorporeal Membrane Oxygenation

Antiviral Therapy

• Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
• Remdesivir
  • Table 2a. Remdesivir: Selected Clinical Data
• Chloroquine or Hydroxychloroquine and/or Azithromycin
  • Table 2b. Chloroquine or Hydroxychloroquine and/or Azithromycin: Selected Clinical Data
• Ivermectin
  • Table 2c. Ivermectin: Selected Clinical Data
• Lopinavir/Ritonavir and Other HIV Protease Inhibitors
• Nitazoxanide
  • Table 2d. Nitazoxanide: Selected Clinical Data
• Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19

Anti-SARS-CoV-2 Antibody Products

• Anti-SARS-CoV-2 Antibody Products (Summary Recommendations)
• Anti-SARS-CoV-2 Monoclonal Antibodies
  • Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
• Convalescent Plasma
  • Table 3b. COVID-19 Convalescent Plasma: Selected Clinical Data
• Immunoglobulins: SARS-CoV-2 Specific
• Table 3c. Characteristics of SARS-CoV-2 Antibody-Based Products Under Evaluation for the Treatment of COVID-19

Cell-Based Therapy Under Evaluation for the Treatment of COVID-19

Immunomodulators

• Immunomodulators Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
• Colchicine
• Corticosteroids
  • Table 4a. Corticosteroids: Selected Clinical Data
• Fluvoxamine
• Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
  • Table 4b. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
• Immunoglobulins: Non-SARS-CoV-2 Specific
• Interferons (Alfa, Beta)
• Interleukin-1 Inhibitors
• Interleukin-6 Inhibitors
  • Table 4c. Interleukin-6 Inhibitors: Selected Clinical Data
• Kinase Inhibitors: Baricitinib and Other Janus Kinase Inhibitors, and Bruton’s Tyrosine Kinase Inhibitors
• Table 4d. Characteristics of Immunomodulators Under Evaluation for the Treatment of COVID-19

Antithrombotic Therapy in Patients With COVID-19

Supplements

• Supplements (Summary Recommendations)
• Vitamin C
• Vitamin D
• Zinc

Considerations for Certain Concomitant Medications in Patients With COVID-19

Special Populations

• Special Considerations in Pregnancy
• Special Considerations in Children
• Special Considerations in Adults and Children With Cancer
• Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients
• Special Considerations in People With HIV
• Influenza and COVID-19

Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics